Share
Susan Rodriguez
Avadel Pharmaceuticals plc, a biopharmaceutical company dedicated to transforming medicines to improve lives, has appointed Susan Rodriguez as Chief Operating Officer.
In this newly created role, Ms. Rodriguez will oversee all aspects of the company’s commercial strategy, structure, organization, and operations, including supply chain management.
Bringing over 30 years of experience in the life sciences industry, Ms. Rodriguez has a proven track record in driving commercial success and operational excellence. She most recently served as Chief Commercial Officer at Ardelyx, where she led the launches of first-in-class therapies in gastroenterology and nephrology and played a pivotal role in transitioning Ardelyx into a fully commercial organization.
Prior to Ardelyx, Ms. Rodriguez was Chief Executive Officer of Tolmar Pharmaceuticals, a specialty oncology company, where she established a new U.S. commercial entity, secured a market-leading position for its primary oncology therapy, advanced the company’s pipeline, and successfully launched a rare disease therapy. Earlier in her career, she held multiple commercial leadership roles across divisions at Abbott and the Abbott–Takeda joint venture, TAP Pharmaceuticals.
Ms. Rodriguez holds both a B.S. and M.S. in psychology from the University of Pennsylvania.
